EMA/PE/0000233446 - paediatric investigation plan
Ifinatamab deruxtecan
PIPHuman
Slovenian is available via eTranslation, the European Commission's machine translation service.
Translate to Slovenian | Important information about machine translation
Key facts
- Active substance
- Ifinatamab deruxtecan
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- EMA/PE/0000233446
- PIP number
- EMA/PE/0000233446
- Pharmaceutical form(s)
- All pharmaceutical forms
- Condition(s) / indication(s)
- Treatment of prostate malignant neoplasms
- Route(s) of administration
- All routes of administration
- Contact for public enquiries
Daiichi Sankyo Europe GmbH
E-mail: service@daiichi-sankyo.eu
Tel.: +49 8978080- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date
- Compliance check done
- Ne